← All stocks

TScan Therapeutics, Inc.

TCRX Net buying

CIK 0001783328 #4673 in the set updated 22 Sep 2026

Bought (120 mo)

$30.36M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$1.02M

$0.00 on a plan · $952.12K straight out of an exercise

Sold at will

$63.95K

3 of 4 sales

Net

+$29.34M

+$30.29M against sales at will

By person

10 insiders · 44 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

BAKER BROS. ADVISORS LP entity

Director

$23.93M (10)

—

+$23.93M

3,848,885

3.0%

$3.46M

+261.7%

Lynx1 Capital Management LP entity

10% owner

$3.64M (8)

$63.95K (3)

+$3.58M

8,019,148

6.2%

$7.21M

+55.4%

Westphal Christoph H

10% owner

$2.00M (1)

—

+$2.00M

1,036,585

0.798%

$931.79K

—

ZDRAVESKI ZORAN

See Remarks

$35.26K (1)

$952.12K (1) scheduled

−$916.86K

4,716

0.004%

$4.24K

−37.1%

BARBERICH TIMOTHY J

Director

$242.02K (3)

—

+$242.02K

67,027

0.052%

$60.25K

—

SOUTHWELL DAVID P

Chief Executive Officer

$185.89K (3)

—

+$185.89K

171,569

0.132%

$154.22K

+97.4%

Silver Brian M.

Chief Financial Officer

$156.71K (6)

—

+$156.71K

32,885

0.025%

$29.56K

—

Klencke Barbara

Director

$107.95K (4)

—

+$107.95K

45,000

0.035%

$40.45K

+80.0%

MacBeath Gavin

Chief Executive Officer

$31.10K (2)

—

+$31.10K

49,767

0.038%

$44.74K

+11.2%

Desmarais William

Chief Business Officer

$22.71K (1)

—

+$22.71K

2,500

0.002%

$2.25K

—

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 95

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 16

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 1

Sales at will 3

Transactions with no price 0

Shares from compensation/vesting 1,384,620

History held since 16 Jul 2021